peptideInjectableNo FGF21 analog is FDA- or EMA-approved as of the cited literature; individual molecules such as efruxifermin and pegozafermin remain investigational, studied in phase 2/3 MASH trials
FGF-21 AnalogBenefits, Dosage & Interactions
FGF-21 (Fibroblast Growth Factor 21) is a hormone primarily produced by the liver, playing a crucial role in regulating metabolism, particularly of glucose and lipids. It acts as an endocrine factor that affects various tissues, including adipose tissue, liver, pancreas, and brain, to maintain metabolic homeostasis.
How much FGF-21 Analog do people take?
The network meta-analyses pool randomized phase 2/3 trials of injectable FGF21 analogs (efruxifermin, pegozafermin) at the doses used in those specific trials for MASH; doses vary by molecule and are not summarized as one range in the cited sources. Route reported: Subcutaneous injection, as used across the FGF21-analog trials pooled in the network meta-analyses. Frequency reported: Weekly or every-other-week dosing schedules, per the individual trials included in the pooled analyses. These are amounts documented in the cited studies and labels for FGF-21 Analog — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 1 human randomized trial published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
1 human randomized trial published.
Plasma half-life
Varies by specific molecule/formulation (e.g., Fc-fusion vs PEGylated); not given as a single value across the class in the cited reviews
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The network meta-analyses pool randomized phase 2/3 trials of injectable FGF21 analogs (efruxifermin, pegozafermin) at the doses used in those specific trials for MASH; doses vary by molecule and are not summarized as one range in the cited sources[1][2]
- Route studied
- Subcutaneous injection, as used across the FGF21-analog trials pooled in the network meta-analyses[1][2]
- Frequency
- Weekly or every-other-week dosing schedules, per the individual trials included in the pooled analyses[1][2]
Reported for FGF-21 Analog in the cited sources. Published ranges are not dosing advice.
Mixing FGF-21 Analog: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, FGF-21 Analog vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the FGF-21 Analog entry is written from. Each number matches an inline marker above.
- [1]Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction-Associated Steatohepatitis: A Network Meta-Analysis of Randomized Controlled TrialsJaber D, Jaber I, Lehia AA, Asad T, Ayesh H · Endocrinology, Diabetes & Metabolism · 2026 · Peer-reviewed · PMID 41947319
- [2]Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysisTsutsumi T, Tang NSY, Ng CH, Suzuki H, Syn NL, Sasikumar NA, et al. · Med · 2026 · Peer-reviewed · PMID 41946364
- [3]The role of fibroblast growth factor 21 in diabetes and metabolic dysfunctionJaiswal A, Nigam C, Singh GN, Gautam AK · Molecular Biology Reports · 2026 · Peer-reviewed · PMID 42313341
What is FGF-21 Analog studied for?
What is FGF-21 Analog?
FGF-21 (Fibroblast Growth Factor 21) is a hormone primarily produced by the liver, playing a crucial role in regulating metabolism, particularly of glucose and lipids. It acts as an endocrine factor that affects various tissues, including adipose tissue, liver, pancreas, and brain, to maintain metabolic homeostasis. FGF-21 Analogs are synthetic peptides designed to mimic or enhance the action of naturally occurring FGF-21. These analogs are being investigated for their therapeutic potential in treating metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). By stimulating similar pathways to endogenous FGF-21, these analogs aim to improve insulin sensitivity, reduce blood glucose levels, promote weight loss, and mitigate hepatic steatosis. Due to its significant effects on metabolic health, FGF-21 and its analogs are also of interest in the context of healthy aging and longevity. As a peptide, FGF-21 Analog is typically administered via injection, reflecting its biological nature and the need to bypass gastrointestinal degradation. (Source: PubChem, DrugBank)
What does the research say about FGF-21 Analog?
Tap a section to expand.
FGF-21 exerts its biological effects by binding to a receptor complex composed of a fibroblast growth factor receptor (FGFR, primarily FGFR1c) and an obligate co-receptor, beta-klotho (KLB). Unlike classical FGFs, FGF-21 does not require heparin for its activity and specifically uses KLB to confer receptor specificity. Once bound, this complex initiates intracellular signaling cascades, primarily through the MAPK/ERK pathway, though other pathways like STAT and PI3K/Akt may also be involved. In adipose tissue, FGF-21 promotes glucose uptake independently of insulin, enhances fatty acid oxidation, and induces adiponectin secretion. In the liver, it inhibits lipogenesis, promotes ketogenesis under fasting conditions, and improves insulin sensitivity. It also influences pancreatic beta-cell function and has effects on the hypothalamus, regulating energy expenditure and appetite. FGF-21 Analogs are engineered to have improved pharmacological properties compared to native FGF-21, such as enhanced stability, extended half-life (e.g., 48 hours for some analogs), and potentially increased potency or specificity, while retaining the ability to activate the FGFR/KLB receptor complex and elicit downstream metabolic improvements. These modifications are critical for their development as therapeutic agents. (Source: DrugBank, PubChem)
The potential benefits of FGF-21 Analogs are primarily centered around metabolic regulation and improvement of conditions associated with metabolic dysfunction:
* **Improved Glucose Metabolism:** FGF-21 Analogs can enhance insulin sensitivity and promote glucose uptake in peripheral tissues, leading to reduced blood glucose levels. This makes them relevant for managing type 2 diabetes.
* **Weight Loss and Body Composition:** Studies suggest that FGF-21 Analogs can induce weight loss, primarily through increased energy expenditure and fat metabolism. They may also improve body composition by reducing fat mass.
* **Reduction in Hepatic Steatosis:** By inhibiting liver lipogenesis and promoting fatty acid oxidation, FGF-21 Analogs can significantly reduce liver fat content, offering a potential treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
* **Improved Lipid Profile:** These analogs have been shown to lower circulating triglyceride levels and improve other aspects of the lipid profile.
* **Cardiovascular Benefits:** By ameliorating metabolic risk factors such as obesity, dyslipidemia, and insulin resistance, FGF-21 Analogs may indirectly confer cardiovascular protection.
* **Potential Longevity Impact:** Given its role in metabolic health and stress response, FGF-21 is being investigated for its potential to impact aging processes and extend healthy lifespan, though direct evidence for longevity in humans with analogs is still emerging. (Source: MedlinePlus, PubChem)
Research into FGF-21 and its analogs spans numerous preclinical and clinical studies. Preclinical studies in various animal models (mice, non-human primates) have consistently demonstrated the potent metabolic benefits of FGF-21 analogs, including significant reductions in body weight, improved glucose tolerance, increased insulin sensitivity, and reversal of NAFLD/NASH phenotypes. For instance, studies published in reputable journals like *Cell Metabolism* have highlighted the weight-reducing and glucose-lowering effects of engineered FGF-21 variants in obese and diabetic animal models. Clinical trials (Phase 1 and Phase 2) of various FGF-21 analogs are underway or have been completed by pharmaceutical companies. These trials have generally shown promising results in human subjects with obesity, type 2 diabetes, and NAFLD/NASH, confirming the glucose-lowering, weight-reducing, and liver fat-reducing effects observed in animal models. Some notable findings include dose-dependent reductions in liver fat content as measured by MRI-PDFF (proton density fat fraction) in patients with NAFLD/NASH, improvements in glycemic control markers like HbA1c, and favorable changes in lipid profiles. Further large-scale, long-term Phase 3 trials are typically needed to fully establish efficacy, safety, and gain regulatory approval. (Source: PubMed studies, clinical trial registries like ClinicalTrials.gov)
While FGF-21 Analogs show promise, potential side effects have been observed in clinical trials and preclinical studies. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and vomiting. Injection site reactions (e.g., pain, redness, swelling) are also possible due to the injectable nature of the compound. Some studies have reported transient increases in heart rate or blood pressure, though their clinical significance often requires further investigation. Less common or more severe side effects could include hypoglycemia, especially when combined with other glucose-lowering medications, or potential effects on bone mineral density, which have been observed in some animal studies but not consistently in humans. Specific adverse event profiles vary significantly between different analog formulations and patient populations. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Individuals considering FGF-21 Analogs should be aware of several warnings. Due to their significant impact on metabolic pathways, close medical supervision is essential, particularly for individuals with pre-existing metabolic conditions. Patients with diabetes, in particular, should monitor their blood glucose levels carefully to avoid hypoglycemia, especially when FGF-21 Analogs are used in conjunction with insulin or sulfonylureas. The long-term effects of FGF-21 Analogs on various organ systems, particularly bone health and cardiovascular function, are still under active investigation, and therefore, caution is warranted. Pregnancy and breastfeeding are generally considered contraindications due to insufficient safety data. Specific warnings may be associated with individual analog formulations as they progress through clinical development and regulatory review. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Contraindications for FGF-21 Analogs generally include known hypersensitivity to the compound or any of its excipients. Given the lack of comprehensive safety data, pregnancy and lactation are typically considered contraindications. Individuals with severe kidney or liver impairment may also be contraindicated or require careful dose adjustments, as the pharmacokinetics of these peptides can be altered. Patients with a history of pancreatitis should use these compounds with caution, as high FGF-21 levels have been implicated in some pancreatic changes, though direct causality in humans with analogs is not fully established. Any severe or uncontrolled chronic illness that could be exacerbated by metabolic shifts induced by FGF-21 Analogs might also be a contraindication. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Caution is advised when mixing FGF-21 Analogs with other medications that significantly impact glucose or lipid metabolism. Concomitant use with insulin or insulin secretagogues (e.g., sulfonylureas) may increase the risk of hypoglycemia and require careful dose adjustments and glucose monitoring. Similarly, combining with other weight-loss medications or agents affecting liver function should be approached with caution due to potential additive or synergistic effects on efficacy and side effects. There is limited specific data on drug-drug interactions, so clinicians should consider the overall pharmacological profile of all co-administered drugs. Users should always inform their healthcare provider of all medications, supplements, and herbal products they are taking. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
FGF-21 Analogs are typically administered via injection. The specific timing and frequency of injections (e.g., daily, weekly, or less frequently) depend on the analog's half-life and the therapeutic regimen determined by a licensed clinician. For instance, an analog with a half-life of 48 hours might support less frequent dosing. The administration can typically occur at any time of day, and generally, there are no specific food rules, meaning it can be taken either with or without food. However, individual product labels or prescribing information will provide precise instructions regarding timing. The dosage must be set by a licensed clinician, taking into account individual patient factors, disease severity, and response to treatment.
Put it into practice
Reading about FGF-21 Analog is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with FGF-21 Analog?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about FGF-21 Analog
FGF-21 is a natural hormone primarily from the liver that regulates glucose and fat metabolism. FGF-21 Analogs are synthetic versions designed to mimic and enhance its effects, primarily by activating cellular receptors (FGFR/beta-klotho complex) to improve insulin sensitivity, reduce blood sugar, promote weight loss, and decrease liver fat.
FGF-21 Analog are primarily being investigated for metabolic disorders such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). Interest also extends to their potential for promoting healthy aging and longevity.
No, as peptides, FGF-21 Analogs are typically administered via injection. This method ensures they are not degraded by the digestive system and can reach their target receptors effectively.
Common side effects can include gastrointestinal issues like nausea, diarrhea, and injection site reactions. More serious concerns, such as hypoglycemia (especially with other diabetes medications) or long-term effects on bone density, are under investigation and should be discussed with a clinician.
No, it is not. FGF-21 Analogs are not recommended for pregnant or breastfeeding individuals due to insufficient safety data. Those with severe kidney or liver issues, or a history of pancreatitis, should also exercise caution. Always consult with a licensed clinician to determine if it is appropriate for you.
FGF-21 Analog is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers FGF-21 Analog with no sign-up.
FGF-21 Analog is administered by injection, so the measured volume — not a tablet count — is the unit that matters. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a peptide like FGF-21 Analog with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against FGF-21 Analog: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for FGF-21 Analog varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of FGF-21 Analog depends on the protocol and formulation you are on. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like FGF-21 Analog the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
The network meta-analyses pool randomized phase 2/3 trials of injectable FGF21 analogs (efruxifermin, pegozafermin) at the doses used in those specific trials for MASH; doses vary by molecule and are not summarized as one range in the cited sources. Route reported: Subcutaneous injection, as used across the FGF21-analog trials pooled in the network meta-analyses. Frequency reported: Weekly or every-other-week dosing schedules, per the individual trials included in the pooled analyses. These are amounts documented in the cited studies and labels for FGF-21 Analog — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at FGF-21 Analog?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH(opens PubMed in a new tab)The New England journal of medicine · 2023 · PMID 37356033 · https://pubmed.ncbi.nlm.nih.gov/37356033/
Verify at
Publisher search links for FGF-21 Analog. These are places to check the information — they are not citations, so they are not numbered.
- PubChem(publisher search, opens in a new tab)National Center for Biotechnology Information · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- ClinicalTrials.gov(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on FGF-21 Analog?
Plain-text summary, safe to quote verbatim:
FGF-21 (Fibroblast Growth Factor 21) is a hormone primarily produced by the liver, playing a crucial role in regulating metabolism, particularly of glucose and lipids. It acts as an endocrine factor that affects various tissues, including adipose tissue, liver, pancreas, and brain, to maintain metabolic homeostasis.
Source: DoseRoutine — https://doseroutine.com/library/fgf-21-analog
FGF-21 Analog cheat sheet
DoseRoutine cheat sheet · Peptide
FGF-21 Analog
FGF-21 (Fibroblast Growth Factor 21) is a hormone primarily produced by the liver, playing a crucial role in regulating metabolism, particularly of glucose and lipids. It acts as an endocrine factor that affects various tissues, including adipose tissue, liver, pancreas, and brain, to maintain metabolic homeostasis.
Evidence
Strong
1 human randomized trial published.
Studied range
The network meta-analyses pool randomized phase 2/3 trials of injectable FGF21 analogs (efruxifermin, pegozafermin) at the doses used in those specific trials for MASH; doses vary by molecule and are not summarized as one range in the cited sources
Route
Subcutaneous injection, as used across the FGF21-analog trials pooled in the network meta-analyses
Frequency studied
Weekly or every-other-week dosing schedules, per the individual trials included in the pooled analyses
Half-life
Varies by specific molecule/formulation (e.g., Fc-fusion vs PEGylated); not given as a single value across the class in the cited reviews
Storage
Refrigerated, per standard handling for injectable protein therapeutics; not itemized in the cited sources
No FGF21 analog is FDA- or EMA-approved as of the cited literature; individual molecules such as efruxifermin and pegozafermin remain investigational, studied in phase 2/3 MASH trialsBlood SugarWeight LossCardiovascular
Key references
- Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction-Associated Steatohepatitis: A Network Meta-Analysis of Randomized Controlled Trials (2026)
- Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis (2026)
- The role of fibroblast growth factor 21 in diabetes and metabolic dysfunction (2026)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/fgf-21-analog
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). FGF-21 Analog — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/fgf-21-analog
What compounds are similar to FGF-21 Analog?
Others in the peptide category or studied for the same goals.
Which goals is FGF-21 Analog used for?
Other compounds studied for the same benefits as FGF-21 Analog.
Continue exploring
See every compound DoseRoutine catalogs for these goals.